ALNOV.PA Stock Analysis
AL
Uncovered
Novacyt SA is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Novacyt SAS engages in the development and sale of cancer and infectious disease diagnostic products. The company is headquartered in Velizy-Villacoublay, Ile-De-France. The company went IPO on 2012-10-12. The firm develops and markets solutions dedicated to the field of liquid-based cytology and molecular biology. The firm provides diagnostic products used in oncology, microbiology, haematology, and serology testing. The firm develops secure automated cytology named NovaPrep Processor System. Novacyt SA offers a solution of cytological sampling to help in the detection of precancerous and cancerous lesions. The firm creates bottles specifically dedicated to the optimization of cell collection. The Company’s range of products includes Bottle Gyn and No Gyn Bottle. Novacyt SA is present in France and internationally through a network of distributors.